子類別 專利 [0/18] 期刊論文 [157/157] 會議論文/會議摘要 [23/37] 鄰近社群 伍素瑩 [52/65] 其他 [58/60] 夏克山 [76/98] 岳嶽 [29/32] 張仲明 [7/9] 張俊彥 [18/18] 張竣評 [21/26] 徐祖安 [170/215] 李秀珠 [75/105] 李靜琪 [23/24] 林書玉 [19/20] 洪明秀 [31/40] 潘秀玲(2009-2013) [16/17] 王文傑 [13/15] 王鴻俊 [7/7] 石全(2014-2017) [35/39] 童俊維 [23/23] 紀雅惠 [21/25] 翁紹華 [22/24] 莊宏 [1/1] 葉修華 [24/25] 葉燈光 [133/152] 蔣維棠 [41/66] 謝興邦 [171/231] 趙宇生(2002-2013) [120/212] 郭靜娟 [49/55] 鄒倫 [28/29] 陳志豪 [31/52] 陳新(2002-2015) [53/67] 顏婉菁 [6/7] 許明珠(1997-2001) [3/10] 陳淑貞(1998-2001) [3/11] 陳華鍵(1997-2001) [9/9] 社群統計 近3年內發表的文件:19(8.96%) 含全文筆數:180(84.91%) 文件下載次數統計 下載大於0次:180(100.00%) 下載大於100次:176(97.78%) 檔案下載總次數:97521(1.82%) 最後更新時間: 2024-12-01 03:19 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 DBPR116, a prodrug of BPRMU191, in ... Discovery of a mu-opioid receptor m... Discovery of a long half-life AURKA... Postfermented tea extract potently ... Natural fucoidans inhibit coronavir... Development of furanopyrimidine-bas... The synergistic inhibition of coron... Omicron-specific mRNA vaccine induc... BPR0C261, an analogous of microtubu... Protective effect of CXCR4 antagoni...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目76-100 / 212. (共9頁) << < 1 2 3 4 5 6 7 8 9 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2016-12	Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation	Oncotarget. 2016 Dec;7(52):86239-86256.
2016-12	Novel cKIT kinase inhibitor, BPRCKJ001, as an advanced therapeutic candidate for GIST	Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 2P.
2016-10	BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT driven myeloid leukemia	Molecular Cancer Therapeutics. 2016 Oct;15(10):2323-2333.
2016-10	Multifunctional nanoparticles for oral protein drug delivery	Diabetes Research and Clinical Practice. 2016 Oct;120(Suppl. 1):S19.
2016-08	Dipeptidyl peptidase-4 inhibitor LAF-237 improves glucose tolerance and expends graft beta cell mass in diabetic mice transplanted with a sufficient number of islets	Diabetologia. 2016 Aug;59(Suppl. 1):S198.
2016-05	N-Indolylglycosides bearing modifications at the glucose C6-Position as Sodium-Dependent Glucose Co-transporter 2 inhibitors	Bioorganic and Medicinal Chemistry. 2016 May;24(10):2242-2250.
2016-02	Multifunctional nanoparticles for oral protein drug delivery	Nanomedicine: Nanotechnology, Biology and Medicine. 2016 Feb;12(2):463.
2015-09	Self-assembling bubble carriers for oral protein delivery	Biomaterials. 2015 Sep;64:115-124.
2015-08	Novel Nrf2/ARE activator, trans-coniferylaldehyde, induces a HO-1-mediated defense mechanism through a dual p38alpha/MAPKAPK-2 and PK-N3 signaling pathway	Chemical Research in Toxicology. 2015 Aug ;28(9):1681-1692.
2015-08	Zinc-dipicolylamine directed pharmaceutical delivery system (ZAPS) as an innovative cancer drug delivery platform	Cancer Research. 2015 Aug;75(Suppl. 15):Abstract number 4413.
2015-08	Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia	Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 490.
2015-07	Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations	European Journal of Medicinal Chemistry. 2015 Jul;100:151-161.
2015-04	IL-1beta promotes malignant transformation and tumor aggressiveness in oral cancer	Journal of Cellular Physiology. 2015 APR;230(4):875-884.
2015-03	Stem cell mobilizers targeting chemokine receptor CXCR4: Renoprotective application in acute kidney injury	Journal of Medicinal Chemistry. 2015 Mar;58(5):2315-2325.
2014-11	Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent	European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93.
2014-10	YYEI motif is critical to oncogenicity of 14-3-3 proteins	Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 3527.
2014-10	Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma	Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756.
2014-08-15	Anticancer oral formulation	特許第5596680號/2014-08-15
2014-08-04	Effects of dipeptidyl peptidase-4 inhibition with MK-0431 on syngeneic mouse islet transplantation	International Journal of Endocrinology. 2014 Aug 4;2014:Article ID 795283.
2014-06-04	抗癌口服制剂	ZL200980126979.4/2014-06-04
2014-04	Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles	Biomaterials. 2014 Apr;35(11):3641-3649.
2014-03	DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study	Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI.
2014-01-08	Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer	PLoS ONE. 2014 Jan 8;9(1):Article number e83160.
2013-11	BPR0C305, an orally active microtubule-disrupting anticancer agent	Anticancer Drugs. 2013 Nov;24(10):1047-1057.
2013-11	A development drug candidate targeting EGFR kinase for lung cancer: DBPR112	Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779-S780.

顯示項目76-100 / 212. (共9頁) << < 1 2 3 4 5 6 7 8 9 > >> 每頁顯示[10|25|50]項目